Brief prescribing information
Download the Brief Prescribing Information for MabThera.
About CLL
Here you can learn more about CLL, including current theories relating to disease aetiology and current practice in diagnosis and classification.
Treating CLL
MabThera is the new standard of care in CLL. MabThera plus chemotherapy significantly improves PFS compared with chemotherapy alone in first-line CLL, maximising remission for these patients.
Standard induction and maintenance therapy in relapsed/refractory FL
MabThera maintenance therapy prolongs response to induction chemotherapy and is approved for patients with relapsed/refractory follicular lymphoma.
MabThera maintenance therapy
MabThera maintenance therapy prolongs response to induction chemotherapy and is approved for patients with relapsed/refractory follicular lymphoma.
MabThera product characteristics
Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.
- Disclaimer: Mabthera.com is a resource for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.